Listl Stefan, Faggion Clovis Mariano
Translational Health Economics Group (THE Group), Heidelberg University, Department of Conservative Dentistry, Heidelberg, Germany; Munich Center for the Economics of Aging, Max-Planck-Institute for Social Law and Social Policy, Munich, Germany.
Department of Periodontology and Operative Dentistry, Faculty of Dentistry, University of Münster, Münster, Germany.
J Evid Based Dent Pract. 2016 Jun;16(2):86-9. doi: 10.1016/j.jebdp.2016.01.001. Epub 2016 Jan 12.
This second article of a series of four is aimed to inform dental practitioners about the relevance to provide more formal analysis of economic resources when helping patients make clinical decisions.
The following methods of health economic evaluation are described: Cost-effectiveness-analysis (CEA), cost-utility-analysis (CUA) and cost-benefit-analysis (CBA). CEA compares the effectiveness of different interventions usually based on specific clinical outcome measures, for example pocket depth reduction. CUA evaluates the effectiveness of therapies by taking into account more generic health outcome measures such as quality adjusted life years (QALYs). Cost-benefit-analysis (CBA) is based on measuring patients' actual willingness to pay. Cost-benefit-analysis (CBA) is based on measuring patients' actual willingness to pay, and it offers a method of economic evaluation that values all benefits against all costs. In other words, the total costs of a specific intervention are subtracted from the value of benefits related to that intervention.
This article reported common methods of health economic evaluation that could be taken into account throughout clinical decision-making. Decision makers (patients, practitioners, health policy) should be adequately informed about costs and health outcomes associated with the various therapeutic alternatives in order to act responsibly within scenarios of resource scarcity. Economic evaluations can be informative with respect to whether or not the health outcomes outweigh the costs of an intervention, and hence provide a decision-making tool for decision makers considering treatment alternatives.
The information provided here may help decision makers (patients, practitioners, health policy) to understand economic considerations as an essential component of the decision-making process. Carefulness is advised with regard to interpreting the results from economic evaluation studies.
本系列四篇文章中的第二篇旨在告知牙科从业者,在帮助患者做出临床决策时,对经济资源进行更正式分析的相关性。
描述了以下健康经济评估方法:成本效果分析(CEA)、成本效用分析(CUA)和成本效益分析(CBA)。CEA通常基于特定的临床结局指标比较不同干预措施的效果,例如牙周袋深度减少。CUA通过考虑更一般的健康结局指标(如质量调整生命年(QALYs))来评估治疗效果。成本效益分析(CBA)基于衡量患者的实际支付意愿。成本效益分析(CBA)基于衡量患者的实际支付意愿,并提供一种经济评估方法,将所有收益与所有成本进行权衡。换句话说,从与特定干预措施相关的收益价值中减去该干预措施的总成本。
本文报告了在整个临床决策过程中可考虑的常见健康经济评估方法。决策者(患者、从业者、卫生政策制定者)应充分了解与各种治疗选择相关的成本和健康结局,以便在资源稀缺的情况下做出负责任的决策。经济评估可以提供有关健康结局是否超过干预成本的信息,从而为考虑治疗选择的决策者提供决策工具。
此处提供的信息可能有助于决策者(患者、从业者、卫生政策制定者)将经济因素理解为决策过程的重要组成部分。在解释经济评估研究结果时建议谨慎。